BWX Technologies, Inc. BWXT
Composite 46/100; the shares have moved about 46% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 25/100 — a strong mark against it.
Growth ranks 67/100 — a moderate point in its favour. Balance-sheet strength ranks 63/100 — a moderate point in its favour.
Valuation ranks 25/100 — a strong mark against it. Momentum ranks 27/100 — a moderate mark against it. Income ranks 46/100 — a slight mark against it.
What the company does BWX Technologies designs, manufactures, and delivers nuclear components for defense, naval, and commercial applications, including reactors, fuel, steam generators, and waste storage systems. Its Government Operations segment serves U.S. and allied programs, while Commercial Operations supplies nuclear fuel and equipment to utilities and research reactors globally.
Key financials BWXT posts strong profitability with ROE 29%, ROA 6%, and net margin 10.2%, supported by revenue growth of 26.1% and EPS growth of 20.7%. Leverage is elevated (Debt/Equity 1.58), though interest coverage stands at 11.1x and current ratio at 2.4x. Valuation metrics are rich: P/E 46.54 (forward 39.37), EV/EBITDA 31.10, and P/B 12.64.
Stock health Momentum is mixed: down 21.77% over 3 months but up 11.57% over 12 months, with a 29.99% drawdown from the 52-week high and RSI(14) at 41.20. Quality pillars are average (overall Sideravia score 47.5), with strength (65.0) and growth (68.5) offset by weak valuation (19.7).
Price vs fair value The stock trades at a PREMIUM of 42.10% versus our fair-value estimate of 97.87 and at a discount of 40.87% versus the analyst 12-month target of 238.16. - Simply Wall St. flags potential overvaluation based on nuclear cash-flow hopes (Simply Wall St.) - JPMorgan’s bullish outlook contrasts with broader valuation skepticism (TheStreet) - Recent U.S.-Saudi atomic deal coverage highlights sector tailwinds (Zacks)
Looking forward Analysts see 40.87% upside to the 12-month target, driven by defense contracts and commercial nuclear demand, but current multiples embed high expectations. Execution on large backlog conversion and margin stability will be key to justifying valuation.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.